Drug intelligence / Profile preview

japanese encephalitis vaccine (vero cell), inactivated

Development stage
Phase 4
Lead developer
Liaoning Chengda Biotechnology
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Japanese encephalitis vaccine (Vero cell), inactivated is a viral vaccine used for the active prevention of Japanese encephalitis, a serious central nervous system infection caused by the Japanese encephalitis virus (JEV) and transmitted by mosquitoes. Developed by companies such as Liaoning Chengda Biotechnology, this specific formulation involves growing the virus in Vero cell cultures, followed by inactivation (usually with formaldehyde) and purification. The vaccine is often produced in a freeze-dried (lyophilized) form to enhance stability and shelf life. It works by inducing the production of neutralizing antibodies against JEV, providing protection to individuals living in or traveling to endemic regions. Clinical trials, including Phase IV safety studies, have been conducted to evaluate its performance as a booster dose in pediatric populations, comparing different manufacturers' formulations.

Brand names
Jevac
Other names
Inactivated Japanese encephalitis vaccine (Vero cell)Freeze-dried inactivated Japanese encephalitis vaccine (Vero cell)
02

Targets

Japanese encephalitis virus-specific B-cell receptor and immunoglobulin (JEV-specific BCR/Ig)Japanese encephalitis virus premembrane/membrane protein and envelope protein (JEV prM/M and E)E (Tick-borne encephalitis virus envelope protein)T-cell receptor recognizing Japanese encephalitis virus peptide-MHC complex

Beyond the preview

Go deeper on japanese encephalitis vaccine (vero cell), inactivated.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on japanese encephalitis vaccine (vero cell), inactivated.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call